348 results match your criteria: "Norwalk Hospital[Affiliation]"

Background: The efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. CCP might prevent infection when administered before symptoms or laboratory evidence of infection.

Methods: This double-blinded, phase 2 randomized, controlled trial (RCT) compared the efficacy and safety of prophylactic high titer (≥1:320 by Euroimmun ELISA) CCP with standard plasma.

View Article and Find Full Text PDF

Babesiosis incidence in the United States has been increasing with an 11% rise between 2018 and 2019 based on the latest CDC annual summary, reaching its highest ever reported incidence. This primarily tick-borne disease is particularly prevalent in New England. Despite predominantly nonspecific and at times subtle symptoms, life-threatening complications do occur.

View Article and Find Full Text PDF

• Cancer of the penis is rare in developed countries. • Left ventricular metastases are very rare and not well documented. • Complications of myocardial infiltration are tamponade, arrythmias, and myocardial rupture.

View Article and Find Full Text PDF

Early Outpatient Treatment for Covid-19 with Convalescent Plasma.

N Engl J Med

May 2022

From the Department of Medicine, Division of Infectious Diseases (K.A.G., S.S.), the Department of Pathology (E.M.B., C.E.M., A.A.R.T.), the Department of Neurology, Brain Injury Outcomes Division (A.Y., K.L., N.A.M., A.L.G., N.K., D.F.H.), the Department of Ophthalmology (D.A.J.), the Welch Center for Prevention, Epidemiology and Clinical Research (L.J.A.), and the Institute for Clinical and Translational Research (D.E.F.), Johns Hopkins School of Medicine, and the Departments of Molecular Microbiology and Immunology (D.J.S., A.S., A.P., S.L.K., A.C.), International Health (L.L.H., C.G.S.), and Epidemiology (B.L., D.M.S., S.E., S.N.B.), Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, Bethesda (O.L.), and Luminis Health, Annapolis (B.R.M.) - all in Maryland; the Department of Medicine, Division of Hematology and Oncology, MedStar Washington Hospital Center (A.G.S.), and the Department of Medicine, Division of Infectious Diseases, Georgetown University Medical Center (S.G.K.) - both in Washington, DC; the Division of Allergy and Immunology, Department of Medicine (G.S.M.), and the Department of Pathology (T.J.G.), NorthShore University Health System, Evanston, IL; the Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine (Y.F.), the Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Texas Health Science Center (B.P.), Houston, and The Next Practices Group, Austin (E.C.F.) - all in Texas; the Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham (S.L.H.); the Department of Emergency Medicine, Rhode Island Hospital, Brown University, Providence, RI (A.C.L.); the Department of Medicine, Division of Infectious Diseases, University of Utah School of Medicine, Salt Lake City (E.S.S.); the Department of Medicine, Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami (S.A.); the Department of Medicine, Division of Infectious Diseases, University of Cincinnati, Cincinnati (M.A.H.); the Department of Medicine, Division of Infectious Diseases, Mayo Clinic Hospital, Phoenix, AZ (J.E.B.); the Department of Medicine, Division of Infectious Diseases, University of California, Los Angeles (J.S.C.), Ascada Research (K.O., M.A.), the Department of Medicine, Division of Infectious Diseases, University of California, Irvine (D.N.F.), and the Department of Medicine, Division of Infectious Diseases, University of California, San Diego (E.R.C.) - all in California; the Department of Emergency Medicine, Wayne State University, Detroit (J.H.P.); the Department of Medicine, Division of Hematology and Oncology, University of Massachusetts Chan Medical School, Worcester (J.M.G.); Nuvance Health (J.R.P., W.R., M.-E.C.), and Nuvance Health Danbury Hospital (P.B.B.), Danbury, and Nuvance Health Norwalk Hospital, Norwalk (J.H., B.G.) - all in Connecticut; Nuvance Health Vassar Brothers Medical Center, Poughkeepsie (V.C.C., D.C.), the Department of Medicine, University of Rochester Medical Center, Rochester (M.S.Z.), and the Bliss Group, New York (M.R.) - all in New York; and the Department of Pathology, University of New Mexico School of Medicine, Albuquerque, NM (J.S.R.).

Background: Polyclonal convalescent plasma may be obtained from donors who have recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in preventing serious complications in outpatients with recent-onset Covid-19 is uncertain.

Methods: In this multicenter, double-blind, randomized, controlled trial, we evaluated the efficacy and safety of Covid-19 convalescent plasma, as compared with control plasma, in symptomatic adults (≥18 years of age) who had tested positive for severe acute respiratory syndrome coronavirus 2, regardless of their risk factors for disease progression or vaccination status.

View Article and Find Full Text PDF

Changes and Implications of Working With Advanced Practitioners in 2023.

Chest

September 2022

Pulmonary, Critical Care and Sleep Medicine, AdventHealth Shawnee Mission, Shawnee Mission, KS.

View Article and Find Full Text PDF

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma.

medRxiv

December 2021

Department of Medicine, Division of Infectious Diseases (S.S., K.G.) Department of Pathology (E.B., C.M. A.T.), Department of Neurology, Brain Injury Outcomes Division (A.Y., K.L., N. M., A.G., N.K. D.H.), Department of Ophthalmology (DJ), Welch Center (L.A.), Institute for Clinical and Translational Research (D.F.), Johns Hopkins University School of Medicine; the Departments of Molecular Microbiology and Immunology (A.C., D.S., S.K., A.P.), International Health (L.H., C.S.), and Epidemiology (B.L., D.S., S.E.) Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH (O.L.); Department of Medicine, Division of Hematology and Oncology, Medstar Washington Hospital Center, Washington, DC (A.S.); Division of Allergy and Immunology, Department of Medicine (G.M.), Department of Pathology (T.G.), Northshore University Health System, Evanston, IL; Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX (Y.F.); Department of Medicine, Divisions of Pulmonary and Critical Care Medicine, University of Texas Health Science Center, Houston, TX (B.P.); Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL (S.H.); Department of Emergency Medicine, Rhode Island Hospital/Brown University, Providence, RI (A.L.); Luminis Health, Annapolis, MD (B. M.); Department of Medicine, Division of Infectious Diseases, University of Utah, Salt Lake City, UT (E.S); Department of Medicine, Division of Infectious Diseases, University of Miami, Miller School of Medicine, Miami, FL (S.A.); Department of Medicine, Division of Infectious Diseases University of Cincinnati, Cincinnati, OH (M.H.); Department of Medicine, Division of Infectious Diseases, Mayo Clinic Hospital, Phoenix, AZ (J.B.); Department of Medicine, Division of Infectious Diseases, University of California, Los Angeles, Los Angeles, CA (J.C.); Department of Emergency Medicine, Wayne State University, Detroit, MI (J.P.); Department of Medicine, Division of Hematology and Oncology, University of Massachusetts, Worchester, MA (J.G.); Nuvance Health, Danbury, CT (J.P., W.R., M.E.C); Nuvance Health Danbury Hospital, Danbury, CT (P.B.); Nuvance Health Norwalk Hospital, Norwalk, CT (J.H., B.G.); Nuvance Health Vassar Brothers Medical Center, Poughkeepsie, NY (V.C., D.C.); Ascada Research, Fullerton, CA (K.O, M.A.); Department of Medicine, Division of Infectious Diseases, University of California, Irvine, Irvine, CA (D.F.); Department of Medicine, University of Rochester, Rochester, NY (M.Z.); Department of Medicine, Division of Infectious Diseases, University of California, San Diego, San Diego, CA (E.C.); Department of Pathology, University of New Mexico, Albuquerque, NM (J.R.); Department of Medicine, Division of Infectious Diseases, Medstar Georgetown University Hospital, Washington, D.C. (S.K.), The Bliss Group, New York City, NY, (M.R.) The Next Practice, Austin, TX (C.F.).

Background: The efficacy of polyclonal high titer convalescent plasma to prevent serious complications of COVID-19 in outpatients with recent onset of illness is uncertain.

Methods: This multicenter, double-blind randomized controlled trial compared the efficacy and safety of SARS-CoV-2 high titer convalescent plasma to placebo control plasma in symptomatic adults ≥18 years positive for SARS-CoV-2 regardless of risk factors for disease progression or vaccine status. Participants with symptom onset within 8 days were enrolled, then transfused within the subsequent day.

View Article and Find Full Text PDF

Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection.

medRxiv

December 2021

Department of Medicine (S.S., K.G., D.T., P.B., J.Z., A.B., L.A., C.M.) Department of Pathology (E.B., A.T.), Department of Neurology (K.L., N.M., D.H., A.G., A.Y.) and the Department of Ophthalmology (DJ), The Johns Hopkins University School of Medicine, Baltimore, MD, Departments of Molecular Microbiology and Immunology (A.C., D.S., S.K., H.S.P., C.A.C., J.R.S., A.P. A.J.) and Epidemiology (B.L., D.S., D.J., S.E.,S.B., C.S.) The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, Mosaic Consulting Ltd., Israel (N.K.), Department of Medicine, Luminis Health, Annapolis, MD (B.M.), Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX (Y.F), Department of Emergency Medicine, Rhode Island Hospital/Brown University, Providence, RI (A.L.), Division of Infectious Diseases/Department of Medicine, Georgetown University Medical Center, Washington, DC (S.K.), Division of Allergy and Immunology, Department of Medicine (G.M.), and Department of Pathology (T.G.), Northshore University Health System, Evanston, IL, Department of Medicine, Division of Infectious Diseases University of Cincinnati, Cincinnati, OH (M.H.), Department of Medicine, Division of Infectious Diseases, University of California, Irvine, Irvine, CA (D.F.), Department of Medicine, Division of Infectious Diseases, University of California, Los Angeles, Los Angeles, CA (J.S.), Department of Medicine, Division of Infectious Diseases (E.C.) and Department of Pathology (E.A.), University of California, San Diego, San Diego, CA, Department of Medicine, Division of Hematology and Oncology, University of Massachusetts, Worchester, MA (J.G.), Department of Medicine, Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL (SA), Department of Medicine, University of Rochester, Rochester, NY (MZ), Department of Neurology, University of Utah, Salt Lake City, UT (J.R.S), Department of Medicine, Division Critical Care Medicine, University of Texas Health, Houston, TX (B.P.), Department of Emergency Medicine Wayne State University, Detroit, MI (J.P.), Danbury Hospital (P.B.), Norwalk Hospital (J.H.), Vassar Brothers Medical Center, Nuvance Health, Poughkeepsie, NY (VC) and University of Vermont (J.P., W.R., M.E.C.), Nuvance Health, Danbury, CT, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health Baltimore, MD (O.L.).

Background: The efficacy of SARS-CoV-2 convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. We hypothesized that CCP might prevent infection when administered before symptoms or laboratory evidence of infection.

Methods: This double-blinded, phase 2 randomized, controlled trial (RCT) compared the efficacy and safety of prophylactic high titer (≥1:320) CCP with standard plasma.

View Article and Find Full Text PDF

State of Women in Medicine: History, Challenges, and the Benefits of a Diverse Workforce.

Pediatrics

September 2021

Department of Orthopaedic Surgery, University of Kansas, Medical Center, Kansas City, Kansas.

Women in medicine have made progress since Elizabeth Blackwell: the first women to receive her medical degree in the United States in 1849. Yet although women currently represent just over one-half of medical school applicants and matriculates, they continue to face many challenges that hinder them from entering residency, achieving leadership positions that exhibit final decision-making and budgetary power, and, in academic medicine, being promoted. Challenges include gender bias in promotion, salary inequity, professional isolation, bullying, sexual harassment, and lack of recognition, all of which lead to higher rates of attrition and burnout in women physicians.

View Article and Find Full Text PDF

Debridement of Diabetic Foot Ulcers.

Adv Wound Care (New Rochelle)

December 2022

Department of Medicine, Norwalk Hospital, Norwalk, Connecticut, USA.

Diabetic foot ulcerations have devastating complications, including amputations, poor quality of life, and life-threatening infections. Diabetic wounds can be protracted, take significant time to heal, and can recur after healing. They are costly consuming health care resources.

View Article and Find Full Text PDF

Purpose The purpose of this study is to compare optic disc dose (ODD) between I and Pd Collaborative Ocular Melanoma Study (COMS) plaques in ocular brachytherapy. Methods A previously validated in-house brachytherapy dose calculation program was used for ODD calculations. ODD was calculated as a function of tumor margin-to-optic disc distance (DT) up to 5 mm for various tumor basal dimensions (BDs), for a prescription depth of 5 mm, and for standard and notched COMS plaques loaded with I (model: IAI-125A) and Pd (model: IAPd-103A) seeds.

View Article and Find Full Text PDF

In this report, we present a case of ventricular fibrillation (VF) arrest in an asymptomatic coronavirus disease 2019 (COVID-19) patient with no cardiac history and normal cardiac workup. Cardiac involvement in COVID-19 has been described previously in hospitalized patients with severe COVID-19. To our knowledge, this is the first report to describe VF arrest in a patient who was incidentally found to have COVID-19.

View Article and Find Full Text PDF

Introduction: Gender preferences have been reported as a barrier to colorectal cancer screening, particularly among women. We aim to identify the role of patients' gender preferences for endoscopists and endoscopy team members, with the effect of age-related and regional differences.

Methods: We conducted an anonymous, voluntary survey of all adult outpatients presenting at our endoscopy centers before their procedures.

View Article and Find Full Text PDF

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.

Ann Oncol

September 2021

Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, USA. Electronic address:

Article Synopsis
  • The ASCENT trial showed that sacituzumab govitecan (SG) significantly improved survival compared to traditional chemotherapy in patients with metastatic triple-negative breast cancer.
  • An exploratory analysis evaluated the impact of tumor Trop-2 expression and BRCA1/2 mutation status on patient outcomes.
  • Results indicated that patients treated with SG had better progression-free survival, overall survival, and response rates, regardless of their Trop-2 expression levels or BRCA1/2 mutation status.
View Article and Find Full Text PDF

A case report of COVID-19 infection and management during pregnancy.

SAGE Open Med Case Rep

May 2021

Department of Obstetrics and Gynecology, Danbury Hospital, Danbury, CT, USA.

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which started in Wuhan, Hubei Province, China, and progressed to a pandemic affecting over 210 countries and territories including the United States. The severity of symptoms range from mild to critical disease involving multi-organ failure; however, many pregnant COVID-19 patients have mild symptoms. The understanding of COVID-19 is evolving and there is limited data about its effects in pregnancy.

View Article and Find Full Text PDF

Purpose: The outbreak of coronavirus disease 2019 (COVID-19) required clinicians to use knowledge of therapeutic mechanisms of established drugs to piece together treatment regimens. The purpose of this study is to examine the trends in medication use among patients with COVID-19 across the United States using a national dataset.

Methods: We conducted a cross-sectional study of the COVID-19 cohort in the Cerner Real-World Data warehouse, which includes deidentified patient information for encounters associated with COVID-19 from December 1, 2019, through June 30, 2020.

View Article and Find Full Text PDF

Purpose: Impaired glucose metabolism is present in most patients with pancreatic ductal adenocarcinoma (PDAC). Whereas previous studies have focused on pre-treatment glycemic indices and prognosis in those with concomitant diabetes, the effects of glycemic control during chemotherapy treatment on prognosis, in patients with and without diabetes, have not been well characterized. We examined the relationship between early glycemic control and overall survival (OS) in a cohort of patients with advanced PDAC treated in a community setting.

View Article and Find Full Text PDF

A Case of Asymptomatic Cardiac Lipoma and Literature Review.

CJC Open

February 2021

Department of Cardiovascular Medicine, Norwalk Hospital, Norwalk, Connecticut, USA.

Primary cardiac tumours are a rare occurrence, of which lipomas comprise approximately 8%. Although mostly asymptomatic, cardiac lipomas can lead to lethal arrhythmias and significant left ventricular outflow obstruction. We present a case of an asymptomatic left ventricular lipoma managed by surgical resection and discuss diagnostic modalities and management options.

View Article and Find Full Text PDF

Objectives: The purpose of this study was to evaluate the diagnostic performance of fine-needle aspiration (FNA) biopsy for intraocular mass-like lesions and its contributing factors.

Methods: Intraocular FNA cases were retrieved and reviewed along with histopathologic follow-ups, if available. The effects of rapid on-site evaluation (ROSE), repeated biopsy, and adjunct immunocytochemical studies on cytologic diagnoses were analyzed.

View Article and Find Full Text PDF

Neuroendocrine prostate cancer (NEPC) is a highly aggressive histologic subtype of prostate cancer associated with a poor prognosis. Its incidence is expected to increase as castration-resistant disease emerges from the widespread use of potent androgen receptor-targeting therapies, such as abiraterone and enzalutamide. Defects in homologous recombination repair genes, such as , are also being increasingly detected in individuals with advanced prostate cancer.

View Article and Find Full Text PDF

Objectives: The goals of this study were to assess the air quality in subway systems in the northeastern United States and estimate the health risks for transit workers and commuters.

Methods: We report real-time and gravimetric concentrations and particle composition from area samples collected in the subways of Philadelphia, Pennsylvania; Boston, Massachusetts; New York City, New York/New Jersey (NYC/NJ); and Washington, District of Columbia. A total of 71 stations across 12 transit lines were monitored during morning and evening rush hours.

View Article and Find Full Text PDF

Precautions for Patients Taking Aromatase Inhibitors.

J Adv Pract Oncol

March 2020

Western Connecticut Health Network at The Smilow Family Breast Health Center, Norwalk Hospital, Norwalk, Connecticut.

Aromatase inhibitors are the drug of choice for the treatment of estrogen receptor- or progesterone receptor-positive breast cancer in postmenopausal women. Aromatase is an enzyme that catalyzes the final and rate-limiting step in the biosynthesis of estrogen. Inhibitors of this enzyme are an effective therapy for breast cancer.

View Article and Find Full Text PDF

is a common bacteria known to cause meningitis and urinary tract infections in neonates and pregnant women, respectively. Recently, has become an increasingly recognized pathogen in non-pregnant adults, manifesting most commonly as skin and soft tissue infections, urinary tract infections (UTIs), and pneumonia. Meningitis and endocarditis are among the most feared complications of due to high morbidity and mortality, especially in adults over 65 years of age.

View Article and Find Full Text PDF

Plasma Insulin-like Growth Factor Binding Protein 7 Contributes Causally to ARDS 28-Day Mortality: Evidence From Multistage Mendelian Randomization.

Chest

March 2021

Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA; Pulmonary and Critical Care Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA. Electronic address:

Background: ARDS is a devastating syndrome with heterogeneous subtypes, but few causal biomarkers have been identified.

Research Question: Would multistage Mendelian randomization identify new causal protein biomarkers for ARDS 28-day mortality?

Study Design And Methods: Three hundred moderate to severe ARDS patients were selected randomly from the Molecular Epidemiology of ARDS cohort for proteomics analysis. Orthogonal projections to latent structures discriminant analysis was applied to detect the association between proteins and ARDS 28-day mortality.

View Article and Find Full Text PDF